Publication date: May 23, 2022 Dopamine replacement therapy with levodopa is the gold standard treatment of Parkinson’s disease (PD); however long-term levodopa use is associated with abnormal involuntary movements known ... Read more

Publication date: May 23, 2022 Introduction: Parkinson’s disease (PD) is characterized by high-rates of depression with limited evidence-based treatment options to improve mood. Objective: To expand therapeutic options, we evaluated ... Read more

Publication date: May 23, 2022 Dopamine cells in the ventral tegmental area (VTA) are critical for a variety of motivated behaviors. These cells receive synaptic inputs from over 100 anatomically-defined ... Read more

Publication date: May 21, 2022 Freezing of gait (FOG) is a common and debilitating gait impairment in Parkinson’s disease. Further insight into this phenomenon is hampered by the difficulty to ... Read more

Publication date: Apr 18, 2022 Neuropsychiatric symptoms are common and important to people with Parkinson’s disease (PD), but their etiology is poorly understood. Plasma neurofilament light (NfL) and p-tau181 are ... Read more

Publication date: Mar 06, 2022 Movement abnormalities, by definition, and cognitive changes, to varying extents, affect every patient with Parkinson’s disease (PD) and are attributed to the underlying neurodegenerative disease. ... Read more